Plans to start Coversin Phase III in PNH in Q1 2018 NEW YORK and LONDON, September 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), a …
[Read more...] about Akari Therapeutics Announces Regulatory Progress Following FDA Meeting
Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
NEW YORK and LONDON, September 19, 2017 – Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce …
Akari Therapeutics Announces Appointment of David Horn Solomon as CEO
NEW YORK and LONDON – Akari Therapeutics (NASDAQ:AKTX, is pleased to announce that Dr David Horn Solomon will be appointed as the company’s new chief executive …
[Read more...] about Akari Therapeutics Announces Appointment of David Horn Solomon as CEO
Akari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
NEW YORK and LONDON, August 10, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, …
Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association
NEW YORK and LONDON, June 23, 2017 -- Akari Therapeutics (NASDAQ: AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd …
